The impact of nutrition in urogenital cancers

Archives of Medical Science

Volumn 11, Issue 2, 2015, Pages 411-418

  Golabek, Tomasz ^a   Powroźnik, Jan ^b   Chłosta, Piotr ^a   Dobruch, Jakub ^b   Borówka, Andrzej ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b European Health Centre   (Poland)

Author keywords

Bladder cancer; Diet; Kidney cancer; Prostate cancer

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BLADDER CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; DIABETES MELLITUS; FAT INTAKE; FOLLOW UP; HUMAN; LIPID DIET; NONHUMAN; NUTRITIONAL DEFICIENCY; NUTRITIONAL STATUS; PROSTATE CANCER; UROGENITAL TRACT CANCER;

EID: 84928400610     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2015.50973     Document Type: Article

References (91)

1. Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F. Trends in mortality from urologic cancers in Europe, 1970-2008. Eur Urol 2011; 60: 1-15.
2. Klimczak A, Kempińska-Mirosławska B, Mik M, Dziki L, Dziki A. Incidence of colorectal cancer in Poland in 1999-2008. Arch Med Sci 2011; 7: 673-8.
3. Levi F, Lucchini F, Negri E, Boyle P, La Vecchia C. Leveling of prostate cancer mortality in Western Europe. Prostate 2004; 60: 46-52.
4. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-52.
5. Silverman D, Devesa S, Moore L, Rothman N. Bladder cancer. In: Cancer epidemiology and prevention. 3rd ed. Schottenfeld D, Fraumeni JF (ed.). Oxford University Press, Oxford 2006; 1101-27.
6. Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008; 101: 11-9.
7. McLaughlin JK, Lipworth L, Tarone RE, Blot W. Renal cancer. In: Cancer epidemiology and prevention. 3rd ed. Schottenfeld D, Fraumeni Jr JF (eds.). Oxford University Press, New York 2006; 1087-100.
8. Levi F, Ferlay J, Galeone C, et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int 2008; 101: 949-58.
9. Cheng G, Xie L. Alcohol intake and risk of renal cell carcinoma: a meta-analysis of published case-control studies. Arch Med Sci 2011; 7: 648-57.
10. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002; 26 (1 Suppl): 1SA-138SA. Erratum in: JPEN J Parenter Enteral Nutr 2002; 26: 144.
11. Muir CS, Nectoux J, Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 1991; 30: 133-40.
12. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63: 963-6.
13. Denis L, Griffiths K, Turkes A. The concept of prevention as a public health strategy for prostate cancer control. Arch Med Sci 2005; 1: 23-33.
14. Bjorge T, Tretli S, Engeland A. Relation of height and body mass index to renal cell carcinoma in 2 million Norwegian men and women. Am J Epidemiol 2004; 160: 1168-76.
15. Andersson SO, Wolk A, Bergström R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385-9.
16. Cerhan JR, Torner JC, Lynch CF, et al. Association of smoking, body mass,and physical activity with risk of prostate cancer in the Iowa 65+ Rural Health Study (United States). Cancer Causes Control 1997; 8: 229-38.
17. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol 1984; 120: 244-50.
18. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10: 345-53.
19. MacInnis RJ, English DR, Gertig DM, Hopper JL, Giles GG. Body size and composition and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12: 1417-21.
20. Gong Z, Neuhouser ML, Goodman PJ, et al. Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-83.
21. Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 63-9.
22. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
23. Koebnick C, Michaud D, Moore SC, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev 2008; 17: 1214-21.
24. Holick CN, Giovannucci EL, Stampfer MJ, Michaud DS. Prospective study of body mass index, height, physical activity, and incidence of bladder cancer in U.S. men and women. Int J Cancer 2007; 120: 140-6.
25. Ecke TH, Schlechte HH, Gunia S, Lenk SV, Loening SA. Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. Urol Oncol 2008; 26: 470-3.
26. Chow WH, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr. Obesity and risk of renal cell cancer. Cancer Epidemiol Biomarkers Prev 1996; 5: 17-21.
27. Bergström A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer - a quantitative review. Br J Cancer 2001; 85: 984-90.
28. Adams KF, Leitzmann MF, Albanes D, et al. Body size and renal cell cancer incidence in a large US cohort study. Am J Epidemiol 2008; 168: 268-77.
29. Calle EE, Kaaks R. Overweight, obesity, and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
30. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 2002; 13: 287-93.
31. Blair A, Fraumeni JF. Geographic patterns of prostate cancer in the United States. J Natl Cancer Inst 1978; 61: 1379-84.
32. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer 1986; 58: 2363-71.
33. Zaridze DG, Boyle P, Smans M. International trends in prostatic cancer. Int J Cancer 1984; 33: 223-30.
34. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst 1995; 87: 652-6.
35. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993; 85: 1571-9.
36. Bishop GA, McMillan MS, Haughton G, Frelinger JA. Signaling to a B-cell clone by Ek, but not Ak, does not reflect alteration of Ak genes. Immunogenetics 1988; 28: 184-92.
37. Ho PJ, Baxter RC. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia. Clin Endocrinol (Oxf) 1997; 46: 333-42.
38. Hietanen E, Bartsch H, Béréziat JC, et al. Diet and oxidative stress in breast, colon and prostate cancer patients: a case-control study. Eur J Clin Nutr 1994; 48: 575-86.
39. Ngo TH, Barnard RJ, Leung PS, Cohen P, Aronson WJ. Insulin-like growth factor I (IGF-I) and IGF binding protein-1 modulate prostate cancer cell growth and apoptosis: possible mediators for the effects of diet and exercise on cancer cell survival. Endocrinology 2003; 144: 2319-24.
40. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington DC, ICR 2007.
41. Riboli E, González CA, López-Abente G, et al. Diet and bladder cancer in Spain: a multi-centre case-control study. Int J Cancer 1991; 49: 214-9.
42. Radosavljevic V, Jankovic S, Marinkovic J, Dokic M. Diet and bladder cancer: a case-control study. Int Urol Nephrol 2005; 37: 283-9.
43. Steineck G, Hagman U, Gerhardsson M, Norell SE. Vitamin A supplements, fried foods, fat and urothelial cancer. A case-referent study in Stockholm in 1985-87. Int J Cancer 1990; 45: 1006-11.
44. Chyou PH, Nomura AM, Stemmermann GN. A prospective study of diet, smoking, and lower urinary tract cancer. Ann Epidemiol 1993; 3: 211-6.
45. Steinmaus CM, Nuñez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000; 151: 693-702.
46. Brinkman MT, Buntinx F, Kellen E, et al. Consumption of animal products, olive oil and dietary fat and results from the Belgian case-control study on bladder cancer risk. Eur J Cancer 2011; 47: 436-42.
47. Faramawi MF, Johnson E, Fry MW, Sall M, Yi Z. Consumption of different types of meat and the risk of renal cancer: meta-analysis of case-control studies. Cancer Causes Control 2007; 18: 125-33.
48. Wynder EL, Mabuchi K, Whitmore WF Jr. Epidemiology of adenocarcinoma of the kidney. J Natl Cancer Inst 1974; 53: 1619-34.
49. Alexander DD, Cushing CA. Quantitative assessment of red meat or processed meat consumption and kidney cancer. Cancer Detect Prev 2009; 32: 340-51.
50. Ritch CR, Wan RL, Stephens LB, et al. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. J Urol 2007; 177: 97-101.
51. McCabe AJ, Wallace JM, Gilmore WS, McGlynn H, Strain SJ. Docosahexaenoic acid reduces in vitro invasion of renal cell carcinoma by elevated levels of tissue inhibitor of metalloproteinase-1. J Nutr Biochem 2005; 16: 17-22.
52. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602-9.
53. Agarwal B, Rao CV, Bhendwal S, et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999; 117: 838-47.
54. Boudreau DM, Yu O, Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010; 9: 603-21.
55. Bansal D, Undela K, D'Cruz S, Schifano F. Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One 2012; 7: e46691.
56. Parada B, Reis F, Pinto A, et al. Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci 2012; 13: 8482-99.
57. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to statins and risk of common cancers: a series of nested case-control studies BMC Cancer 2011; 11: 409.
58. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-32.
59. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-94.
60. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-7.
61. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin 2010; 60: 207-21.
62. Lindblad P, Chow WH, Chan J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999; 42: 107-12.
63. Washio M, Mori M, Khan M, et al.; JACC Study Group. Diabetes mellitus and kidney cancer risk: the results of Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study). Int J Urol 2007; 14: 393-7.
64. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49: 2819-23.
65. Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer 1998; 77: 1508-13.
66. Chow WH, Gridley G, Fraumeni JF Jr, Järvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343: 1305-11.
67. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2056-62.
68. Bansal D, Bhansali A, Kapil G, Undela K, Tiwari P. Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis 2013; 16: 151-8, S1.
69. Calton BA, Chang SC, Wright ME, et al. History of diabetes mellitus and subsequent prostate cancer risk in the NIH-AARP Diet and Health Study. Cancer Causes Control 2007; 18: 493-503.
70. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992; 117: 807-11.
71. Betancourt-Albrecht M, Cunningham GR. Hypogonadism and diabetes. Int J Impot Res 2003; 15 Suppl 4: S14-20.
72. Ma J, Li H, Giovannucci E, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008; 9: 1039-47.
73. Bosaeus I. Nutritional support in multimodal therapy for cancer cachexia. Support Care Cancer 2008; 16: 447-51.
74. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-84.
75. Alves A, Panis Y, Mathieu P, Mantion G, Kwiatkowski F, Slim K. Postoperative mortality and morbidity in French patients undergoing colorectal surgery: results of a prospective multicenter study. Arch Surg 2005; 140: 278-83.
76. Schiesser M, Kirchhoff P, Müller MK, Schäfer M, Clavien PA. The correlation of nutrition risk index, nutrition risk score, and bioimpedance analysis with postoperative complications in patients undergoing gastrointestinal surgery. Surgery 2009; 145: 519-26.
77. Oh CA, Kim DH, Oh SJ, et al. Changes of preoperative and postoperative nutritional status in patients with gastric cancer and assessment of nutritional factors correlated with short-term postoperative complications. J Korean Gastric Cancer Assoc 2010; 10: 5-12.
78. Kim HL, Belldegrun AS, Freitas DG, et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 2003; 170: 1742-6.
79. Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS. Cachexia-like symptoms predict a worse prognosis in localized T1 renal cell carcinoma. J Urol 2004; 171: 1810-3.
80. Morgan TM, Tang D, Stratton KL, et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur Urol 2011; 59: 923-8.
81. Hollenbeck BK, Miller DC, Taub DA, et al. The effects of adjusting for case mix on mortality and length of stay following radical cystectomy. J Urol 2006; 176: 1363-8.
82. Gregg JR, Cookson MS, Phillips S, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol 2011; 185: 90-6.
83. Enig B, Winther E, Hessov I. Nutritional status of patients with cancer of the bladder before and during radiation therapy. Influence on survival? Radiother Oncol 1986; 5: 277-85.
84. Terry WJ, Bueschen AJ. Complications of radical cystectomy and correlation with nutritional assessment. Urology 1986; 27: 229-32.
85. Huffman DM, Johnson MS, Watts A, Elgavish A, Eltoum IA, Nagy TR. Cancer progression in the transgenic adenocarcinoma of mouse prostate mouse is related to energy balance, body mass, and body composition, but not food intake. Cancer Res 2007; 67: 417-24.
86. Neugut AI, Rosenberg DJ, Ahsan H, et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998; 7: 869-73.
87. Moyad MA, Carroll PR. Lifestyle recommendations to prevent prostate cancer, part I: time to redirect our attention? Urol Clin North Am 2004; 31: 289-300.
88. Naschitz JE, Yeshurun D, Abrahamson J, et al. Ischemic heart disease precipitated by occult cancer. Cancer 1992; 69: 2712-20.
89. Filippatos TD, Rizos EC, Gazi IF, et al. Differences in metabolic parameters and cardiovascular risk between American Diabetes Association and World Health Organization definition of impaired fasting glucose in European Caucasian subjects: a cross-sectional study. Arch Med Sci 2013; 9: 788-95.
90. Gundogan K, Bayram F, Gedik V, et al. Metabolic syndrome prevalence according to ATP III and IDF criteria and related factors in Turkish adults. Arch Med Sci 2013; 9: 243-53.
91. Zhu J, Su X, Li G, Chen J, Tang B, Yang Y. The incidence of acute myocardial infarction in relation to overweight and obesity: a meta-analysis. Arch Med Sci 2014; 10: 855-62.